Literature DB >> 23042022

Interferon-α for unresectable progressive and symptomatic plexiform neurofibromas.

Rejin Kebudi1, Fatma B Cakir, Omer Gorgun.   

Abstract

Neurofibromas are the most common manifestations of neurofibromatosis type-1. They occasionally cause pain or progressive loss of function due to nerve compression. Optimal treatment approach is still challenging and the current treatment results are not satisfactory. Four cases of plexiform neurofibromas with various clinical presentations and an addendum to a previously published report on a patient who had relief from pain and/or regression of tumor volume after treatment with interferon-α 2a are presented.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23042022     DOI: 10.1097/MPH.0b013e318270cd24

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

2.  Advanced pharmacological therapies for neurofibromatosis type 1-related tumors.

Authors:  Thomas Foiadelli; Matteo Naso; Amelia Licari; Alessandro Orsini; Mariasole Magistrali; Chiara Trabatti; Sabino Luzzi; Mario Mosconi; Salvatore Savasta; Gian Luigi Marseglia
Journal:  Acta Biomed       Date:  2020-06-30

3.  Plexiform Neurofibroma: A Case Report.

Authors:  Georgi Tchernev; Anastasiya Atanasova Chokoeva; James W Patterson; Ilko Bakardzhiev; Uwe Wollina; Claudio Tana
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.